Multi-omics Market
Get a free sample of this report
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Request Sectional Data
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Multi-omics Market size was valued at USD 2.9 billion in 2022 and is estimated to grow at a CAGR of 15.2% between 2023 and 2032. One of the primary drivers is the continuous evolution and refinement of omics technologies. Advances in spatial genomics, transcriptomics, proteomics, metabolomics, and other omics disciplines contribute to the generation of vast and intricate datasets, providing researchers with a more comprehensive understanding of biological systems.
Additionally, the increasing adoption of multi-omics approaches in various research domains, from basic biological studies to clinical applications, is fuelling market growth. Furthermore, the rising demand for personalized medicine and targeted therapies amplifies the market's expansion. All these aforementioned factors collectively contribute to the advancement of the market.
Multi-omics refers to an approach in biological research that involves the integration of data from multiple omics disciplines. Omics disciplines include genomics, transcriptomics, proteomics, metabolomics, and other omics fields that aim to characterize and quantify the components of biological systems.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Multi-omics Market size in 2022: | USD 2.9 Billion |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 - 2032 CAGR: | 15.2 |
2023 Value Projection: | USD 12.2 Billion |
Historical Data for: | 2018 to 2022 |
No of Pages: | 210 |
Tables, Charts & Figures: | 376 |
Segments Covered: | Products & Services, Type, Platform, Application, End-use, & Region |
Growth Drivers: |
|
Pitfalls Challenges: |
|
The COVID-19 pandemic had a positive impact on the multi-omics market. Multi-omics analysis platforms played a crucial role in the diagnosis and classification of COVID-19. The urgency to understand the virus and its effects on human biology has accelerated research in these areas, fostered the demand for multi-omics technologies. Also, the pandemic highlighted the importance of comprehensive data integration and analysis to unravel the complexities of disease pathways and host responses. The long-term impact of COVID-19 on the market is likely to include sustained growth as researchers continue to leverage these technologies for a deeper understanding of complex biological systems.
As these technologies become more sophisticated and accessible, their application in research, diagnostics, and therapeutic development has expanded, thereby driving the demand for multi-omics solutions.
Based on products & services, the market is segmented into products & services. The products segment is further segmented into instruments, consumables, and software. The products segment dominated the market in 2022 with a revenue of USD 1.7 billion.
Based on the type, the multi-omics market is bifurcated into single cell multi-omics and bulk omics. The single cell omics segment dominated the market in 2022 with a market share of 72.6%.
Based on the platform, the multi-omics market is categorized into genomics, transcriptomics, proteomics, metabolomics, and integrated omics platforms. The genomics segment is anticipated to grow at a CAGR of 15% between 2023 - 2032.
By application, the multi-omics market is categorized into cell biology, oncology, neurology, immunology, and other applications. The oncology segment is poised for high growth and is anticipated to reach USD 3.3 billion by 2032.
By end-use, the multi-omics market is segmented into academic & research organizations, pharmaceutical & biotechnology companies, hospital and diagnostic laboratories, and other end-users. Wide application of multi-omics data in research, is anticipated to propel the growth of academic and research organizations.
North America accounted for the largest market share of 46.8% of the global multi-omics market in 2022.
The market is characterized by diverse players competing in the industry. Becton, Dickinson and Company, Thermo Fisher Scientific Inc., and Illumina, Inc. account for significant market share. These prominent players thrive through a combination of strategic initiatives, investing in research and development, geographical expansion, strategic approaches, product diversification, and regulatory compliance. The foremost market players operating in the multi-omics industry is as mentioned below:
By Product & Services, 2018 – 2032 (USD Million)
By Type, 2018 – 2032 (USD Million)
By Platform, 2018 – 2032 (USD Million)
By Application, 2018 – 2032 (USD Million)
By End-use, 2018 – 2032 (USD Million)
The above information is provided for the following regions and countries:
Becton, Dickinson and Company, Thermo Fisher Scientific Inc., Illumina, Inc, Danaher, PerkinElmer Inc., Shimadzu Corporation, Bruker, QIAGEN, Agilent Technologies, Inc., and BGI among others.
North America market accounted for a revenue share of 46.8% in 2022 and will showcase high growth rate through 2032, attributed to substantial investments in R&D, a robust infrastructure for healthcare innovation, and a proactive regulatory environment fostering the adoption of multi-omics approaches.
The global multi-omics industry was valued at USD 2.9 billion in 2022 and is estimated to grow at a CAGR of 15.2% between 2023 and 2032, owing to the continuous evolution and refinement of omics technologies.
The oncology application is poised to reach USD 3.3 billion by 2032, as the integration of genomics, transcriptomics, proteomics, and metabolomics has allowed researchers and clinicians to unravel the complex landscape of cancer at a molecular level, paving the way for more targeted therapies.